Copyright ©2010 Baishideng. All rights reserved
World J Gastroenterol. Jun 28, 2010; 16(24): 2963-2970
Published online Jun 28, 2010. doi: 10.3748/wjg.v16.i24.2963
Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors
Jonathan Strosberg, Larry Kvols
Jonathan Strosberg, Larry Kvols, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States
Author contributions: Strosberg J wrote this article and Kvols L reviewed it.
Correspondence to: Jonathan Strosberg, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States. jonathan.strosberg@moffitt.org
Telephone: +1-813-7457257 Fax: +1-813-7457229
Received: February 23, 2010
Revised: March 24, 2010
Accepted: March 31, 2010
Published online: June 28, 2010

Somatostatin analogs were initially developed for the control of hormonal syndromes associated with neuroendocrine tumors (NETs). In recent years, accumulating data has supported their role as antiproliferative agents, capable of stabilizing tumor growth in patients with metastatic neuroendocrine malignancies, including carcinoid and pancreatic endocrine tumors. A phase III, randomized, placebo-controlled trial has now demonstrated that octreotide long-acting repeatable (LAR) 30 mg can significantly prolong time to tumor progression among patients with metastatic midgut NETs regardless of functional status, chromogranin A level or age. In addition to significantly lengthening time to tumor progression in the overall study population, subset analysis suggests that patients with low tumor burden are most likely to experience disease stabilization with octreotide LAR 30 mg, supporting the early use of octreotide LAR in patients with metastatic disease. Further research efforts are underway to evaluate the use of somatostatin analogs as antiproliferative agents in other types of gastroenteropancreatic-NETs. Ongoing studies are also evaluating novel somatostatin analogs and somatostatin analogs in combination with other anti-tumor therapies.

Keywords: Somatostatin analogues, Neuroendocrine tumors, Antiproliferative